Mentioned in ?
References in periodicals archive ?
This latest patent supports Molecular Health's discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth.
Combined, Molecular Healthos multiple patents detail methods of determining whether a cancer patient is suitable for EPO therapy inter alia by identifying the level of expression of a novel erythropoietin receptor, EPHB4.